Study focal freezing for intermediate-risk prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether freezing only the cancer area in the prostate (focal cryotherapy) can control intermediate-risk prostate cancer. It aims to limit treatment to one tumor focus while closely checking results with targeted and follow-up testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult man who can speak English and sign consent
- Your prostate cancer is limited to the prostate (no spread seen on scans, up to stage T2bN0M0)
- Your MRI shows a visible tumor area, and you had an MRI-guided biopsy of that specific area plus standard biopsy cores
- Your cancer grade is Grade Group 2 or 3 in a single main focus (no Grade Group 4 or 5)
- Your PSA is not too high (PSA 15 or less, or if higher then PSA density under 0.15)
- You have never been treated for prostate cancer before, and you have not had certain prostate or rectal procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at outcomes after “focal therapy,” a type of treatment that targets only part of the prostate, for people with newly diagnosed or returning prostate cancer. It may help researchers understand how well this targeted approach works and for whom.
This study tracks men with intermediate-risk prostate cancer who had a newer, targeted treatment that only treats the cancer area, not the whole prostate. It aims to see how well these treatments work in real life and may help guide future care.
This trial tests a gentler treatment called focal therapy that targets only the part of the prostate with cancer. It's for men whose prostate cancer has a Gleason score of 7, low PSA, and hasn't spread outside the prostate.
This study tracks outcomes for men who choose cryotherapy (freezing cancer cells) to treat prostate cancer that hasn't spread. It helps doctors understand how well this treatment works.
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
This study is tracking men who choose focal therapy (a targeted treatment) for their localized prostate cancer. It aims to learn how well this treatment works and how it affects quality of life.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.